Clinical trials: Hematopoietic Malignancies
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
The purpose of this study is to: Test the safety of the research study drug, lenalidomide, when given with Idarubicin and Cytarabine See how many respond to combination treatment with lenalidomide, Idarubicin and Cytarabine See…
- Trial name
- NCT00831766
- Testing
- Idarubicin, Cytarabine, Lenalidomide (Revlimid®)
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neuroblastoma
Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation
The purpose of this study is to evaluate the feasibility and efficacy of reduced-intensity allogeneic stem cell transplantation (RIST) with RIC regimen in children with neuroblastoma who have failed a prior autologous stem cell…
- Trial name
- NCT00793351
- Testing
- Reduced-intensity allogeneic hematopoietic stem cell transplantation
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Samsung Medical Center
Hematopoietic and Lymphoid Cell Neoplasm
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
This phase II trial studies the how well donor stem cell transplant works in treating patients with high risk hematologic malignancies.
- Trial name
- NCT03032783
- Testing
- Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hematopoietic System--Cancer
Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML
No more datas about post-transplant cyclophosphamide (PT/Cy) used in pediatric refractory acute myeloid leukemia (R-AML）patients.
- Trial name
- NCT03654703
- Testing
- Cyclophosphamide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Capital Research Institute of Pediatrics
Malignant Hematologic Neoplasm
Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients
This study will highlight that Enteral Nutrition (EN) is as effective in nutritionally supporting as Parenteral Nutrition (PN) in this group of patients undergoing an autologous hematopoietic stem cell transplantation (AHSCT).
- Trial name
- NCT04024618
- Testing
- Parenteral Nutrition/Enteral Nutrition
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma
506U78 in Treating Patients With Refractory Hematologic Cancer
Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00002970
- Testing
- nelarabine, methotrexate, cytarabine
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancies
Extracorporal Photopheresis Pilot Study
ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson \& Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allowed it: 2 ECP per week the first 2 weeks…
- Trial name
- ECP (NCT00930566)
- Testing
- methoxsalen, Extracoporal Photopheresis (ECP)
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Disease, Neurologic Autoimmune Disease
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic…
- Conditions
- Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant
- Trial name
- NCT00716066
- Testing
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Leukemia, Chronic Myelogenous Leukemia (CML)
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
1703: The study is designed as a randomized, phase III, multicenter trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens: tacrolimus/methotrexate (Tac/MTX) versus post-transplant…
- Conditions
- Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
- Trial name
- 1703/1801 (NCT03959241)
- Testing
- Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate
- Where
- 39 sites in United States
- Volunteers
- 431 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia (AML)
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML
The purpose of this prospective phase III, open-label, randomized multicenter study is to evaluate whether Acute Myeloid Leukemia (AML) elderly patients in Complete Remission (CR) undergoing allogeneic hematopoietic stem cell…
- Trial name
- GITMO-AMLR2 (NCT01191957)
- Testing
- Busulphan plus Cyclophosphamide, Busulphan plus Fludarabine
- Where
- 26 sites in Israel, Italy
- Volunteers
- 252 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Sickle Cell Disease, Thalassemia, Beta
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow.
- Conditions
- Sickle Cell Disease, Thalassemia, Beta, Thalassemia
- Trial name
- NCT05736419
- Testing
- Fludarabine, Cyclophosphamide, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity.
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT07634536
- Testing
- VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02037256
- Testing
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukemia ALL
Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia
The study is a monocentric, interventional study that evaluates the efficacy of allogeneic HLA-matched or haploidentical transplantation consisting of an irradiation-based conditioning regimen coupled with donor Treg/Tcon…
- Conditions
- Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukemia ALL, High Risk Leukaemia, Leukaemia Relapse
- Trial name
- SHARP (NCT06845592)
- Testing
- total marrow/lymphoid irradiation
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- University Of Perugia
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated…
- Trial name
- NCT05711667
- Testing
- Biospecimen Collection, Letermovir
- Where
- 33 sites in United States
- Volunteers
- 105 people
- Sponsor
- Children's Oncology Group
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439292
- Testing
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
This pilot clinical trial aims to assess feasibility and tolerability of using an LINAC based "organ-sparing marrow-targeted irradiation" to condition patients with high-risk hematological malignancies who are otherwise…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT02122081
- Testing
- radiation therapy, cyclophosphamide, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumithira Vasu
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03624530
- Testing
- Tyrosine kinase inhibitor (TKIs)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diabetes Mellitus, Cancer
Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant
This clinical research studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation.
- Trial name
- NCT03415139
- Testing
- Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma
Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells
This study is a randomized controlled, open and multi-center clinical study. Patients who meet the selection criteria and do not meet the exclusion criteria are randomly given PEG-rhG-CSF with a fixed dose of 12mg when white…
- Trial name
- NCT06026995
- Testing
- PEG-rhG-CSF, RhG-CSF
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Chongqing University Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.